Hepatotoxicity · HIV‐negative people at risk of TB infection1
Rifampicin plus isoniazid showed no clear difference in hepatotoxicity compared with isoniazid (low certainty).
1 finding from 1 review
Adherence · HIV‐negative people at risk of TB infection1
It is very uncertain whether rifampicin plus pyrazinamide changes adherence compared with isoniazid (very low certainty).
1 finding from 1 review
Treatment‐limiting adverse events · HIV‐negative people at risk of TB infection1
Rifampicin plus pyrazinamide leads to higher treatment‐limiting adverse events compared with isoniazid (high certainty).
1 finding from 1 review
Hepatotoxicity · HIV‐negative people at risk of TB infection1
Rifampicin plus pyrazinamide probably leads to higher hepatotoxicity compared with isoniazid (moderate certainty).
1 finding from 1 review
Active TB · HIV‐negative people at risk of TB infection1
It is very uncertain whether rifampicin plus pyrazinamide changes active TB: compared with isoniazid (very low certainty).
1 finding from 1 review
total treatment failure · patients with human Brucellosis
Doxycycline+Rifampicin probably leads to higher total treatment failure compared with doxycycline+Streptomycin (moderate certainty).
1 finding from 1 review
Minor adverse drug reactions · patients with human Brucellosis
Doxycycline+Rifampicin showed no clear difference in minor adverse drug reactions compared with doxycycline+Streptomycin (low certainty).
1 finding from 1 review
Clinical failure clinical observation · infants with BCG vaccine adverse reactions1
It is very uncertain whether oral isoniazid plus rifampicin changes clinical failure clinical observation compared with no intervention (very low certainty).
1 finding from 1 review
Recurrence · people with Buruli ulcer, non‐ulcerated lesions measuring less than 10 cm in diameter, aged 15 years or older
It is very uncertain whether rifampicin combined with streptomycin changes recurrence, 12 months compared with surgery alone (very low certainty).
1 finding from 1 review
Intervention not reported
True‐positives (patients correctly classified as rifampicin resistant)
1 finding from 1 review
Intervention not reported
False‐negatives (patients incorrectly classified as rifampicin susceptible)
1 finding from 1 review
Intervention not reported
True‐negatives (patients correctly classified as rifampicin susceptible)
1 finding from 1 review
Intervention not reported
False‐positives (patients incorrectly classified as rifampicin resistant)
1 finding from 1 review
Pruritus · participants with cholestatic pruritus (CP)
1 finding from 1 review
Quality of life ‐ not measured · participants with cholestatic pruritus (CP)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Patient satisfaction ‐ not measured · participants with cholestatic pruritus (CP)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Depression ‐ not measured · participants with cholestatic pruritus (CP)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Risk for at least one adverse event per patient · participants with cholestatic pruritus (CP)
It is very uncertain whether summary of findings table ‐ Rifampin/rifampicin changes risk for at least one adverse event per patient compared with placebo (very low certainty).
1 finding from 1 review
Intervention not reported
False positivespeople incorrectly classified as having isoniazid resistance · adults with pulmonary tuberculosis irrespective of rifampicin resistance (i.e. whether or not their rifampicin resistance status was…
1 finding from 1 review
Intervention not reported
Test result · adults with pulmonary tuberculosis irrespective of rifampicin resistance (i.e. whether or not their rifampicin resistance status was…
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found